Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test
Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test
复制标题
DOI:
10.1016/j.parkreldis.2017.02.007
复制
发表时间:
2017-06-01
影响因子:
4.1
通讯作者:
Ferreira, Joaquim J.
中科院分区:
文献类型:
--
作者:
Fabbri, Margherita;Coelho, Miguel;Ferreira, Joaquim J.
Background: Non-motor symptoms (NMS) are extremely common among late-stage Parkinson's disease (LSPD) patients. Levodopa (L-dopa) responsiveness seems to decrease with disease progression but its effect on NMS in LSPD still needs to be investigated.Objective: To assess the response of blood pressure (BP), pain, fatigue and anxiety to L-dopa in LSPD patients.Methods: 20 LSPD patients, defined as Schwab and England ADL Scale 3 (MED ON) and 22 PD patients treated with subthalamic deep brain stimulation (advanced PD group) underwent an L-dopa challenge. BP and orthostatic hypotension (OH) assessment, a visual analogue scale (VAS) for pain and fatigue and the Strait Trait Anxiety (STAI) were evaluated before and after the L-dopa challenge.Results: Systolic BP dropped significantly after L-dopa intake (p < 0.05) in LSPD patients, while there was no change in pain, fatigue or anxiety. L-dopa significantly improved (p < 0.05) pain and anxiety in the advanced PD group, whereas it had no effect on BP or fatigue. L-dopa-related adverse effects (AEs), namely OH and sleepiness, were more common among LSPD patients. 40% and 65% of LSPD patients were not able to fill out the VAS and the STAI, respectively, while measurement of orthostatic BP was not possible in four LSPD patients.Conclusions: This exploratory study concludes that some non-motor variables in LSPD do not benefit from the acute action of L-dopa while it can still induce disabling AEs. There is a need for assessment tools of NMS adapted to these disabled LSPD patients. (C) 2017 Elsevier Ltd. All rights reserved.